Fresh Tracks Therapeutics Inc.
Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Fresh Tracks Therapeutics Inc. (FRTX) - Net Assets
Latest net assets as of December 2023: $9.93 Million USD
Based on the latest financial reports, Fresh Tracks Therapeutics Inc. (FRTX) has net assets worth $9.93 Million USD as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.59 Million) and total liabilities ($1.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.93 Million |
| % of Total Assets | 85.71% |
| Annual Growth Rate | 3.49% |
| 5-Year Change | 31.11% |
| 10-Year Change | -80.88% |
| Growth Volatility | 166.66 |
Fresh Tracks Therapeutics Inc. - Net Assets Trend (1990–2023)
This chart illustrates how Fresh Tracks Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Fresh Tracks Therapeutics Inc. (1990–2023)
The table below shows the annual net assets of Fresh Tracks Therapeutics Inc. from 1990 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $9.93 Million | +38.03% |
| 2022-12-31 | $7.19 Million | -71.12% |
| 2021-12-31 | $24.91 Million | -8.21% |
| 2020-12-31 | $27.14 Million | +258.27% |
| 2019-12-31 | $7.57 Million | -84.47% |
| 2018-12-31 | $48.76 Million | -23.30% |
| 2017-12-31 | $63.58 Million | +40.85% |
| 2016-12-31 | $45.14 Million | -0.56% |
| 2015-12-31 | $45.39 Million | -12.57% |
| 2014-12-31 | $51.92 Million | -15.45% |
| 2013-12-31 | $61.41 Million | -31.06% |
| 2012-12-31 | $89.09 Million | +47.62% |
| 2011-12-31 | $60.35 Million | -6.24% |
| 2010-12-31 | $64.36 Million | +17.06% |
| 2009-12-31 | $54.98 Million | +13.10% |
| 2008-12-31 | $48.61 Million | -39.17% |
| 2007-12-31 | $79.91 Million | -29.98% |
| 2006-12-31 | $114.12 Million | +42.11% |
| 2005-12-31 | $80.31 Million | -3.14% |
| 2004-12-31 | $82.91 Million | -7.70% |
| 2003-12-31 | $89.82 Million | -21.42% |
| 2002-12-31 | $114.31 Million | -19.59% |
| 2001-12-31 | $142.16 Million | -5.73% |
| 2000-12-31 | $150.79 Million | +289.65% |
| 1999-12-31 | $38.70 Million | -5.15% |
| 1998-12-31 | $40.80 Million | -13.56% |
| 1997-12-31 | $47.20 Million | -2.48% |
| 1996-12-31 | $48.40 Million | -9.19% |
| 1995-12-31 | $53.30 Million | +91.04% |
| 1994-12-31 | $27.90 Million | -13.89% |
| 1993-12-31 | $32.40 Million | +281.18% |
| 1992-12-31 | $8.50 Million | +844.44% |
| 1991-12-31 | $900.00K | -71.88% |
| 1990-12-31 | $3.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Fresh Tracks Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16656300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $60.00K | 0.60% |
| Other Components | $182.03 Million | 1833.16% |
| Total Equity | $9.93 Million | 100.00% |
Fresh Tracks Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Fresh Tracks Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Asian Citrus Holdings Limited
PINK:ACITF
|
$2.98 Million |
|
Rostra AG
F:3330
|
$2.98 Million |
|
ROPER TECHNOLOGIES (ROP.SG)
STU:ROP
|
$2.98 Million |
|
Fiducial Office Solutions
PA:SACI
|
$2.98 Million |
|
CIENA (CIE1.SG)
STU:CIE1
|
$2.98 Million |
|
STRYKER
BE:SYK
|
$2.98 Million |
|
ImagineAR Inc
OTCQB:IPNFF
|
$2.98 Million |
|
Bangun Karya Perkasa Jaya
JK:KRYA
|
$2.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fresh Tracks Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 7,194,000 to 9,930,000, a change of 2,736,000 (38.0%).
- Net loss of 5,694,000 reduced equity.
- New share issuances of 6,569,000 increased equity.
- Other factors increased equity by 1,861,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.69 Million | -57.34% |
| Share Issuances | $6.57 Million | +66.15% |
| Other Changes | $1.86 Million | +18.74% |
| Total Change | $- | 38.03% |
Book Value vs Market Value Analysis
This analysis compares Fresh Tracks Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.43x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.43x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1990-12-31 | $1304.53 | $0.72 | x |
| 1991-12-31 | $332.84 | $0.72 | x |
| 1992-12-31 | $3078.59 | $0.72 | x |
| 1993-12-31 | $10204.72 | $0.72 | x |
| 1994-12-31 | $6791.63 | $0.72 | x |
| 1995-12-31 | $12171.73 | $0.72 | x |
| 1996-12-31 | $9889.66 | $0.72 | x |
| 1997-12-31 | $9581.81 | $0.72 | x |
| 1998-12-31 | $8092.03 | $0.72 | x |
| 1999-12-31 | $7555.64 | $0.72 | x |
| 2000-12-31 | $24127.07 | $0.72 | x |
| 2001-12-31 | $22355.55 | $0.72 | x |
| 2002-12-31 | $17933.36 | $0.72 | x |
| 2003-12-31 | $14083.14 | $0.72 | x |
| 2004-12-31 | $11508.75 | $0.72 | x |
| 2005-12-31 | $10291.68 | $0.72 | x |
| 2006-12-31 | $11436.32 | $0.72 | x |
| 2007-12-31 | $6423.28 | $0.72 | x |
| 2008-12-31 | $3842.40 | $0.72 | x |
| 2009-12-31 | $3678.46 | $0.72 | x |
| 2010-12-31 | $3374.33 | $0.72 | x |
| 2011-12-31 | $2639.20 | $0.72 | x |
| 2012-12-31 | $3264.42 | $0.72 | x |
| 2013-12-31 | $2227.66 | $0.72 | x |
| 2014-12-31 | $1842.12 | $0.72 | x |
| 2015-12-31 | $1558.50 | $0.72 | x |
| 2016-12-31 | $1419.20 | $0.72 | x |
| 2017-12-31 | $1553.92 | $0.72 | x |
| 2018-12-31 | $703.26 | $0.72 | x |
| 2019-12-31 | $112.75 | $0.72 | x |
| 2020-12-31 | $49.81 | $0.72 | x |
| 2021-12-31 | $13.96 | $0.72 | x |
| 2022-12-31 | $2.56 | $0.72 | x |
| 2023-12-31 | $1.68 | $0.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fresh Tracks Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -57.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -71.12%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 1.17x
- Recent ROE (-57.34%) is below the historical average (-56.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1990 | -53.13% | -94.44% | 0.41x | 1.38x | $-2.02 Million |
| 1991 | -255.56% | -95.83% | 0.96x | 2.78x | $-2.39 Million |
| 1992 | -23.53% | -55.56% | 0.30x | 1.40x | $-2.85 Million |
| 1993 | -4.32% | -23.33% | 0.17x | 1.08x | $-4.64 Million |
| 1994 | -15.77% | -80.00% | 0.18x | 1.09x | $-7.19 Million |
| 1995 | -7.50% | -63.49% | 0.11x | 1.03x | $-9.33 Million |
| 1996 | -10.54% | -76.12% | 0.13x | 1.08x | $-9.94 Million |
| 1997 | -11.86% | -71.79% | 0.15x | 1.07x | $-10.32 Million |
| 1998 | -18.38% | -127.12% | 0.13x | 1.10x | $-11.58 Million |
| 1999 | -17.83% | -64.49% | 0.24x | 1.17x | $-10.77 Million |
| 2000 | -5.65% | -111.77% | 0.05x | 1.08x | $-23.60 Million |
| 2001 | -6.50% | -81.29% | 0.07x | 1.09x | $-23.46 Million |
| 2002 | -24.44% | -398.62% | 0.05x | 1.13x | $-39.36 Million |
| 2003 | -27.22% | -302.65% | 0.07x | 1.23x | $-33.43 Million |
| 2004 | -28.63% | -163.17% | 0.14x | 1.22x | $-32.02 Million |
| 2005 | -30.33% | -202.92% | 0.13x | 1.18x | $-32.39 Million |
| 2006 | -20.28% | -157.04% | 0.12x | 1.10x | $-34.56 Million |
| 2007 | -44.92% | -651.20% | 0.06x | 1.13x | $-43.89 Million |
| 2008 | -75.90% | -463.75% | 0.13x | 1.21x | $-41.76 Million |
| 2009 | -51.94% | -225.11% | 0.19x | 1.23x | $-34.06 Million |
| 2010 | -47.21% | -348.81% | 0.12x | 1.13x | $-36.82 Million |
| 2011 | -12.07% | -24.26% | 0.44x | 1.14x | $-13.32 Million |
| 2012 | -25.70% | -130.71% | 0.18x | 1.08x | $-31.81 Million |
| 2013 | -50.87% | -404.74% | 0.12x | 1.08x | $-37.38 Million |
| 2014 | -31.76% | -108.38% | 0.26x | 1.12x | $-21.68 Million |
| 2015 | -20.35% | -44.10% | 0.42x | 1.10x | $-13.78 Million |
| 2016 | -19.88% | -61.75% | 0.28x | 1.16x | $-13.49 Million |
| 2017 | -20.38% | -93.78% | 0.17x | 1.27x | $-19.32 Million |
| 2018 | -33.33% | -1002.10% | 0.03x | 1.07x | $-21.13 Million |
| 2019 | -342.55% | -327.71% | 0.44x | 2.40x | $-26.70 Million |
| 2020 | -77.03% | -1147.26% | 0.05x | 1.24x | $-23.62 Million |
| 2021 | -158.67% | -9782.43% | 0.01x | 1.19x | $-42.01 Million |
| 2022 | -287.20% | -297.58% | 0.68x | 1.43x | $-21.38 Million |
| 2023 | -57.34% | -71.12% | 0.69x | 1.17x | $-6.69 Million |
Industry Comparison
This section compares Fresh Tracks Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fresh Tracks Therapeutics Inc. (FRTX) | $9.93 Million | -53.13% | 0.17x | $2.98 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |